European Heart Journal: Cardiovascular Pharmacotherapy, 7(4), (doi: 10.1016/j.jchf.2021.04.005) (PMID: 34119470)Īdherence to prescribed medications in patients with heart failure – insights from liquid chromatography-tandem mass spectrometry-based urine analysis. Heart failure hospitalization in adults receiving maintenance hemodialysis and effect of intravenous iron therapy: A report from PIVOTAL. Response by Lee et al to letter regarding article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". The effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Sodium–glucose co-transporter 2 inhibitors-the first successful treatment for heart failure with preserved ejection fraction? European Journal of Heart Failure, 23(8), Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer. (doi: 10.1002/ejhf.2308) (PMID: 34272791)Įffect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Journal of Heart Failure, 23(10), European Journal of Heart Failure,Įfficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Circulation,ĭapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. Impact of sacubitril/valsartan versus ramipril on total heart failure events in the PARADISE-MI trial. Kidne圓60, 2(11),Įfficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Stroke in hemodialysis patients randomized to different intravenous iron strategies: a prespecified analysis from the PIVOTAL trial. European Journal of Heart Failure, 23(12), Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry. Heart failure and atrial flutter: a systematic review of current knowledge and practices. High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. Heart,ĭiabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction. (doi: 10.1002/ejhf.2419) (PMID: 34969175)Ĭost-effectiveness of transcatheter edge to edge repair in secondary mitral regurgitation. JACC: CardioOncology,Įffect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. and Lang, N.Ĭardiovascular toxicity of BRAF and MEK inhibitors in patients with cancer: mechanistic and clinical overview. Pathophysiology and risk factors of peripartum cardiomyopathy. F., Arany, Z., Bauersachs, J., Hilfiker-Kleiner, D., Petrie, M. Resting and exercise haemodynamic characteristics of patients with advanced heart failure and preserved ejection fraction. Professor Petrie has a major interest in mentoring future high-caliber cardiologists and has supervised many outstanding individuals during their PhDs and MDs. He was an author of the 2011 European Society of Cardiology NSTEMI Guidelines and a reviewer of the 2016 ESC Heart Failure Guidelines. He has leadership roles in many trials including STICH, REVIVED, REDUCE-LAP, PARADISE-MI, Dapa-HF and IRONMAN. Mark has published around 130 original manuscripts including many in high impact journals such as the New England Journal of Medicine, the Lancet, the European Heart Journal, JACC and Circulation. He established and chaired the Scottish Heart Failure Hub 2014-2017. He worked as a heart failure and interventional cardiologist for many years before transferring to the University of Glasgow in 2016. Mark was Director of the Scottish National Advanced Heart Failure Service 2010-2014 and has served on the National Advisory Committee for Heart Disease 2004-2018. Professor Mark Petrie was an undergraduate in Edinburgh University before training in cardiology in Glasgow.
0 kommentar(er)
